Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 2/2012

01-06-2012 | Review

Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review

Authors: Giuseppe Colloca, Antonella Venturino, Franco Checcaglini

Published in: Medical Oncology | Issue 2/2012

Login to get access

Abstract

The results of cytotoxic therapy in the second-line setting of metastatic castration-resistant prostate cancer have demonstrated that disease is poorly controlled after taxane resistance with a time to progression of 3 months or less. Many trials of second-line chemotherapy have been disappointing. However, most of patients with docetaxel-pretreated castration-resistant disease receive a second-line chemotherapy. Molecular mechanism of castration resistance and docetaxel resistance is resumed, and clinical trials of second-line chemotherapy after docetaxel progression are reviewed. Reintroduction of docetaxel after a drug-free interval is an active treatment in docetaxel-pretreated patients, and only recently a prospective study documented a survival benefit of 2.4 months after second-line taxane-based chemotherapy of metastatic docetaxel-resistant prostate cancer. Although a second-line chemotherapy with a taxane could improve overall survival, a change of biology of castration-resistant prostate cancer after docetaxel is suggested, as inferred by the renewed hormonal sensitivity, whose role on survival remains unknown, and from the activity of antiangiogenic drugs.
Literature
1.
Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765–81.PubMedCrossRef
2.
Tannock IF, Osoba D, Stockler MR, Scott Ernst D, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–64.PubMed
3.
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al., for the TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512.
4.
Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.PubMedCrossRef
5.
Holzbeierlein J, Lal P, La Tulippe E, Smith A, Satagopan J, Zhang L, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol. 2004;164:217–27.PubMedCrossRef
6.
Colloca G, Venturino A, Checcaglini F. Localized androgen-independent prostate cancer. Cancer Ther. 2007;5:485–500.
7.
Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B study 9663. J Clin Oncol. 2003;21:2673–8.PubMedCrossRef
8.
Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Clin Oncol. 1993;11(4):607–15.PubMed
9.
Hodgson MC, Astapova I, Cheng S, Lee LJ, Verhoeven MC, Choi E, et al. The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem. 2005;280:6511–9.PubMedCrossRef
10.
Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004;22:1025–33.PubMedCrossRef
11.
Mostaghel EA, Montgomery B, Nelson PS. Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol Oncol. 2009;27:251–7.PubMedCrossRef
12.
Best CJM, Gillespie JW, Yi Y, Chandramouli GVR, Perlmutter MA, Gathright Y, et al. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res. 2005;11:6823–34.PubMedCrossRef
13.
Morgenbesser SD, McLaren RP, Richards B, Zhang M, Akmaev VR, Winter SF, et al. Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model. Prostate. 2007;67:83–106.PubMedCrossRef
14.
Hsieh AC, Small EJ, Ryan CJ. Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development. Lancet Oncol. 2007;8:933–9.PubMedCrossRef
15.
16.
Beekman KW, Fleming MT, Scher HI, Slovin SF, Ishill NM, Heller G, et al. Second-line chemotherapy for prostate cancer: patient characteristics and survival. Clin Prostate Cancer. 2005;4(2):86–90.PubMed
17.
Yonemori K, Katsumata N, Uno H, Matsumoto K, Kouno T, Tokunaga S, et al. Efficacy of weekly paclitaxel in patients with docetaxel-resistant breast cancer. Breast Cancer Res Treat. 2005;89:237–41.PubMedCrossRef
18.
Di Lorenzo G, Buonerba C, Faiella A, Rescigno P, Rizzo M, Autorino R, et al. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int. 2010, June 29 [Epub ahead of print].
19.
Urakami S, Yoshino T, Kikuno N, Imai SH, Yoneda T, Kishi H, et al. Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study. Urology. 2005;65:543–8.PubMedCrossRef
20.
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al., for the TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet Oncol 2010;376:1147–1154.
21.
Gleave M, Miyake H, Chi K. Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. Cancer Chemother Pharmacol. 2005;56:s47–57.CrossRef
22.
Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer; data from Southwest Oncology Group trial 9346 (INT-0162). J Clin Oncol. 2006;24:3984–90.PubMedCrossRef
23.
Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol. 1993;11:2167–72.PubMed
24.
Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol. 1994;12:1868–75.PubMed
25.
Aragon-Ching JB, Dahut WL. Chemotherapy in androgen-independent prostate cancer (AIPC): what’s next after taxane progression? Cancer Ther. 2007;5:151–60.
26.
Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol. 2009;27:5431–8.PubMedCrossRef
27.
Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients. Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 2007;110:556–63.PubMedCrossRef
28.
Fleming MT, Kolodziej MA, Awasthi S, Hutson TE, Martincic D, Sonpavde G, et al. Results of a randomized phase II study of mitoxantrone versus mitoxantrone with cetuximab in metastatic castrate-resistant prostate cancer (CRPC) previously treated with docetaxel-based chemotherapy. J Clin Oncol. 2010;28(15S):355S.
29.
Berger ER, Ciuleanu T, Hart L, Chi KN, Alexandre J, Oudard S, et al. Result of a randomized phase II study of irofulven in hormone-refractory prostate cancer patients that have failed first-line docetaxel treatment. J Clin Oncol. 2007;25(18S):251s.
30.
de Bono JS, Fizazi K, Flechon A, Heidenreich A, Voog E, Davis NB, et al. Randomized phase II study of CNTO 328 (C), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone (M) versus M alone in metastatic castration-resistant prostate cancer (CRPC). In: Proc genitourinary cancers symposium, poster session (abstract no. 86). 2010.
31.
Saad F, Hotte SJ, North SA, Eigl BJ, Chi KN, Czaykowski P, et al. A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1st-line docetaxel therapy. J Clin Oncol. 2008;26(15S):250s.
32.
Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, et al., for the Prostate Cancer Clinical Trials Consortium. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer. 2008;112:521–526.
33.
Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn D, Ross RW, et al. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int. 2008;101:308–12.PubMedCrossRef
34.
Reuter CW, Morgan MA, Ivanyi P, Fenner M, Ganser A, Gruenwald V. Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer. World J Urol. 2010;28:391–8.PubMedCrossRef
35.
Chatta GS, Feinstein TM, Appleman LJ, Friedland DM, Jacobs SA, Evans TL, et al. Oxaliplatin and docetaxel in castration-resistant prostate cancer (CRPC) patients treated with up to two prior chemotherapeutic regimens: updated results of a phase II trial. J Clin Oncol. 2008;26(15S):286s.
36.
Caffo O, Sava T, Comploj E, Giampaolo MA, Segati R, Valduga F, et al. Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone. Urol Oncol. 2010;28:152–6.PubMedCrossRef
37.
Di Lorenzo G, Figg WD, Fossa SD, Mirone V, Autorino R, Longo N, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol. 2008;54(5):1089–94.PubMedCrossRef
38.
Epplen R, Pfister DJ, Thuer D, Brehmer B, Heidenreich A. The combination of docetaxel and bevacizumab as a second-line therapy in patients with HRPCA and PSA relapse. In: Proc genitourinary cancers symposium, poster session (abstract no. 97). 2010.
39.
Heidenreich A, Pfister DA, Thuer D, Epplen R, Firek P, Brehmer B. Docetaxel rechallenge versus docetaxel/bevacizumab in castration-resistant prostate cancer following first-line docetaxel. In: Proc genitourinary cancers symposium, poster session (abstract no. 178). 2010.
40.
Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, De Rubertis G, et al. Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel. BJU Int. 2007;100(4):775–9.PubMedCrossRef
41.
Poiesz B, Reeves J, McNulty W, Maleski J, Holmlund J, Leopold L. Preliminary report of an open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel and prednisone in men with docetaxel refractory prostate cancer. J Clin Oncol. 2009;27(15S):270s.
42.
Cathomas R, Rothermundt C, van Moos R, Betticher DC, Winterhalder RC, Droege C, et al. Cetuximab in combination with docetaxel in patients with metastatic castration-resistant and docetaxel-refractory prostate cancer: a multicenter phase II trial (SAKK 08/07). J Clin Oncol. 2010;28(15S):383s.
43.
Sella A, Yarom N, Zismas A, Kovel S. Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer. Oncology. 2009;76(6):442–6.PubMedCrossRef
44.
Beer TM, Ryan C, Alumkal J, Ryan CW, Sun J, Eilers KM. A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Anticancer Drugs. 2010;21(4):433–8.PubMedCrossRef
45.
Wilding G, Chen Y, DiPaola RP, Carducci MA, Liu G. E3803: updated results on phase II study of a weekly schedule of BMS-247550 for patients with castrate refractory prostate cancer (CRPC). J Clin Oncol. 2008;26(15S):267s.
46.
Beardsley EK, Saad F, Eigl B, Venner P, Hotte S, Winquist E, Ko YJ, et al. A phase II study of patupilone in patients with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel. J Clin Oncol. 2009;27(15S):268s.
47.
Hussain A, DiPaola RS, Baron AD, Higano CS, Tchekmedyian NS, Johri AR. Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol. 2009;20:492–7.PubMedCrossRef
48.
Stein MN, Chen Y, Hudes GR, Carducci MA, Tan W, DiPaola RS. ECOG 5805: a phase II study of eribulin mesilate (E7389) in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(15S):355s.
49.
de Bono JS, Maroto P, Calvo E, Sonpavde G, Cartwright TH, Loesch D, et al. Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer (CRPC) stratified by prior taxane therapy. In: Proc genitourinary cancers symposium, poster session (abstract no. 166). 2009.
50.
Nakabayashi M, Ling J, Xie W, Regan MM, Oh WK. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. Cancer J. 2007;13(2):125–9.PubMedCrossRef
51.
Oh WK, Manola J, Babcic V, Harnam N, Kantoff PW. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology. 2006;67:1235–40.PubMedCrossRef
52.
Morales R, Valverde C, Suarez C, Brana I, Planas J, Padros O, et al. Mitoxantrone as second-line chemotherapy in patients with castrate-resistant prostate cancer (CRPC). Ann Oncol 2010;21(S8):viii 301.
53.
Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF, on behalf of the TAX 327 investigators. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008;19:1749–1753.
54.
Michels J, Montemurro T, Murray N, Kollmannsberger C, Chi NK. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Cancer. 2006;106(5):1041–6.PubMedCrossRef
55.
Small E, Harzstark A, Weinberg VK, Smith DC, Mathew P, Beer T, et al. Ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer refractory to docetaxel-based therapy: a phase II study of the DOD Prostate Cancer Clinical Trials Consortium. J Clin Oncol. 2009;27(15S):248s.
56.
Lainakis G, Nikos A, Gerassimos A, Michael C, Iraklis M, Konstantinos L, et al. Biweekly doxorubicin/ketoconazole as second-line treatment in docetaxel-resistant, hormone-refractory prostate cancer. Urology. 2008;71:1181–5.PubMedCrossRef
57.
Montanari M, Fabbri F, Frassineti L, Rondini E, Mattioli R, Luzi Fedeli S, et al. Phase II trial of nonpegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer: a translational study. J Clin Oncol. 2010;28(15S):387s.
58.
Kasimis B, Chang VT, Zhong F, Gonzalez ML, Srinivas S, Cogswell J, et al. A second-line trial of epirubicin, estramustine phosphate, and high-dose celecoxib for patients with hormone-resistant prostate cancer. In: Proc genitourinary cancers symposium, poster session (abstract no. 89). 2010.
59.
Latif T, Wood L, Connell C, Smith DC, Vaughn D, Lebwohl D, et al. Phase II study of oral bis (aceto) ammine dichloro (cycloexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). Investig New Drugs. 2005;23:79–84.CrossRef
60.
Vaishampayan UN, Heilbrun LK, Dickow B, Heath EI, Smith D, Baranowski K, et al. Phase II trial of combination therapy with intravenous bevacizumab, oral satraplatin, and prednisone in docetaxel-pretreated metastatic castration-resistant prostate cancer. In: Proc genitourinary cancers symposium, poster session (abstract no. 208). 2010.
61.
Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol. 2009;20:703–8.PubMedCrossRef
62.
Dorff TB, Groshen SG, Wei D, Korn C, Goldkorn A, Quinn DI, et al. Interim results of a phase II trial of pemetrexed, oxaliplatin as 2nd/3rd line therapy in hormone refractory prostate cancer. J Clin Oncol. 2008;26:284s.
63.
Blesa JM, Marco VG, Giner-Bosch V, Cerezuela P, Candel VA. Phase II trial of oxaliplatin and capecitabine after progression to first-line chemotherapy in androgen-independent prostate cancer patients. Am J Clin Oncol. 2010, June 9 [Epub ahead of print].
64.
Ladoire S, Eymard JC, Zanetta S, Mignot G, Martin E, Kermarrec I, et al. Metronomic oral cyclophosphamide-prednisone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure. Anticancer Res. 2010;30(10):4317–23.PubMed
65.
Nelius T, Klatte T, de Riese W, Haynes A, Filleur S. Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy. Med Oncol. 2010;27(2):363–7.PubMedCrossRef
66.
Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, et al. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res. 2009;15(15):4954–62.PubMedCrossRef
67.
Michaelson D, Bellmunt J, Lewis N, Goel S, Lee RJ, Kaufman DS, et al. Phase II study of trabectedin in men with castration resistant prostate cancer. In: Proc genitourinary cancers symposium, poster session (abstract no. 175). 2009.
68.
Hahn NM, Zon RT, Yu M, Ademuyiwa FO, Jones T, Dugan W, et al. A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GUO3-67. Ann Oncol. 2009;20:1971–6.PubMedCrossRef
69.
Caffo O, Fratino L, Perin A, Barbieri R, Sava T, Segati R, et al. Pemetrexed in castration-resistant prostate cancer (CRPC) patients resistant to docetaxel: results of a multicentric phase II study. In: Proc genitourinary cancers symposium, poster session (abstract no. 98). 2010.
70.
Di Lorenzo G, Autorino R, Giuliano M, Morelli E, Giordano A, Napodano A, et al. Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer. Urology. 2007;69:347–51.PubMedCrossRef
71.
Jankovic B, Beardsley E, Chi KN. Rechallenge with docetaxel as second-line chemotherapy in patients with metastatic hormone refractory prostate cancer after previous docetaxel: a population based analysis. In: Proc genitourinary cancers symposium, poster session (abstract no. 196). 2010.
72.
Ansari J, Choo B, Hussain SA, Zarkar A, Ansari A, Tanguay JS, et al. Docetaxel retreatment as second- and third-line chemotherapy in metastatic hormone refractory prostate cancer patients pretreated with docetaxel: an updated analysis. In: Proc genitourinary cancers symposium, poster session (abstract no. 185). 2009.
73.
Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, et al. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer. 2010;46:1770–2.PubMedCrossRef
74.
Firek P, Pfister DA, Thuer D, Brehmen B, Epplen R, Heidenreich A. Docetaxel rechallenge at PSA relapse after docetaxel chemotherapy at hormone refractory prostate cancer. In: Proc genitourinary cancers symposium, poster session (abstract no. 93). 2010.
75.
Eymard JC, Oudard S, Gravis G, Ferrero JM, Theodore C, Joly F, et al. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int. 2010;106(7):974–8.PubMedCrossRef
76.
Gernone A, Troccoli G, Pagliarulo V, Pagliarulo A. Retreatment with docetaxel in metastatic castration-resistant prostate cancer. In: Proc genitourinary cancers symposium, poster session (abstract no. 143). 2010.
77.
Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer. 2003;89:968–70.PubMedCrossRef
78.
Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, et al., ASCENT Investigators. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 2008;112(1):326–330.
79.
Cabrespine A, Guy L, Khenifar E, Curè H, Fleury J, Penault-Llorca F, et al. Randomized phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer. Urology. 2006;67(2):354–9.PubMedCrossRef
80.
Fontana A, Bocci G, Galli L, D’Arcangelo M, Derosa L, Fioravanti A, et al. Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer. J Am Geriatr Soc. 2010;58:986–8.PubMedCrossRef
81.
Armstrong AJ, George DJ. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2010;13:108–16.PubMedCrossRef
82.
Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2010;16(1):203–11.PubMedCrossRef
83.
Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010;28:1496–501.PubMedCrossRef
84.
Nakabayashi M, Oh WK, Jacobus S, Regan MM, Taplin ME, Kantoff PW, et al. Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer. BJU Int. 2010;105(10):132–9.
85.
Shamash J, Davies A, Ansell W, Mcfaul S, Wilson P, Oliver T, et al. A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer. Br J Cancer. 2008;98:22–4.PubMedCrossRef
86.
Van Allen EM, Ryan CJ. Novel secondary hormonal therapy in advanced prostate cancer: an update. Curr Opin Urol. 2009;19(3):315–21.PubMedCrossRef
87.
Bonkhoff H, Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol. 2009;55:533–42.PubMedCrossRef
88.
Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda T, Shigeno K, et al. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res. 2006;12(20):6116–24.PubMedCrossRef
89.
George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, et al.; Cancer and Leukemia Group B 9480. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001;7(7):1932–1936.
90.
Araujo J, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, et al. Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: a phase I/II study. J Clin Oncol. 2009;27(15S):249s.
Metadata
Title
Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review
Authors
Giuseppe Colloca
Antonella Venturino
Franco Checcaglini
Publication date
01-06-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-9855-6

Other articles of this Issue 2/2012

Medical Oncology 2/2012 Go to the issue

Original Paper

Effect of rs6983267 polymorphism in the 8q24 region and rs4444903 polymorphism in EGF gene on the risk of sporadic colorectal cancer in Iranian population

Original Paper

Magnetic resonance imaging is appropriate for determining the osteotomy plane for appendicular osteosarcoma after neoadjuvant chemotherapy

Case Report

Reversible posterior leukoencephalopathy induced by carboplatin and etoposide

Original Paper

Meat intake and risk of bladder cancer: a meta-analysis

Original Paper

PTP1B expression contributes to gastric cancer progression

Original Paper

Clinical implications of mismatched repair gene promoter methylation in pancreatic cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits